Exact Sciences (EXAS) Projected to Post Earnings on Thursday

Exact Sciences (NASDAQ:EXAS - Get Free Report) will likely be announcing its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $688.58 million for the quarter. Exact Sciences has set its FY 2025 guidance at EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $713.42 million during the quarter, compared to analysts' expectations of $701.45 million. On average, analysts expect Exact Sciences to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Exact Sciences Price Performance

EXAS stock opened at $44.09 on Thursday. The company's 50-day moving average price is $45.50 and its two-hundred day moving average price is $54.54. Exact Sciences has a 12 month low of $39.97 and a 12 month high of $72.83. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The firm has a market cap of $8.19 billion, a P/E ratio of -7.92 and a beta of 1.14.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Benchmark restated a "buy" rating and set a $65.00 target price on shares of Exact Sciences in a research note on Monday, January 13th. Mizuho assumed coverage on Exact Sciences in a research note on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price objective on the stock. William Blair reissued an "outperform" rating on shares of Exact Sciences in a research note on Thursday, February 20th. Bank of America decreased their price target on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Finally, Guggenheim reissued a "buy" rating and issued a $60.00 price objective on shares of Exact Sciences in a research note on Friday, April 11th. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $69.25.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.